Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631701 | 0.82 | MAP2 (0.53) | MAP2KDM4EALDH1A1FOLH1EGFR | |
| SCHEMBL2983431 | 0.81 | MAP2 (0.51) | MAP2KDM4EALDH1A1FOLH1EGFR | |
| SCHEMBL4033965 | 0.80 | MAP2 (0.50) | MAP2KDM4EALDH1A1FOLH1EGFR | |
| SCHEMBL4666069 | 0.78 | MAP2 (0.48) | MAP2KDM4EALDH1A1FOLH1EGFR | |
| SCHEMBL5279031 | 0.77 | MAP2 (0.57) | MAP2KDM4EALDH1A1FOLH1EGFR | |
| SCHEMBL28746390 | 0.76 | MCL1 (0.57) | MAP2KDM4EALDH1A1FOLH1EGFR | |
| SCHEMBL4042667 | 0.76 | MAP2 (0.46) | MAP2KDM4EALDH1A1FOLH1EGFR | |
| SCHEMBL4262908 | 0.75 | KDM4E (0.62) | MAP2KDM4EALDH1A1FOLH1EGFR | |
| SCHEMBL5495499 | 0.75 | HTR6 (0.66) | MAP2KDM4EALDH1A1FOLH1EGFR | |
| SCHEMBL9266502 | 0.74 | MAP2 (0.50) | MAP2KDM4EALDH1A1FOLH1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741361-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | claimed |
| EP-1836166-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-09-26 | — | — | EP | claimed |
| US-20060154925-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-07-13 | — | — | US | claimed |
| WO-2006071609-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | WO | claimed |
| US-7741361-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1836166-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMA (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1836166-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20060154925-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2006071609-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154925-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | MAP2 2176/4885KDM4E 3404/4885ALDH1A1 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.